175 results
8-K
CHRS
Coherus Biosciences Inc
5 Jun 24
Departure of Directors or Certain Officers
9:11am
appointed to serve on the Audit Committee of the Board.
Ms. Karachun, age 61, served at Merck & Co., Inc. as SVP and Global Controller from March 2014 … to receive an annual cash retainer for service on the Board and the Audit Committee in the amount of $60,000. On June 4, 2024, Ms. Karachun received
8-K/A
EX-10.1
CHRS
Coherus Biosciences Inc
21 May 24
Financial Statements and Exhibits
5:14pm
of unaudited, interim financial statements, subject to normal year-end audit adjustments and the exclusion of certain footnotes, and any supporting schedules … discretion of the Collateral Agent) audit any Credit Party’s Books. The foregoing inspections and audits, if any, shall be at the relevant Credit Party’s
8-K/A
EX-10.2
CHRS
Coherus Biosciences Inc
21 May 24
Financial Statements and Exhibits
5:14pm
or requirements of any applicable U.S. national securities exchange applicable to the Seller or any of its Equity Interests.
“Audit Arbitrator … , the Buyer may cause an inspection and/or audit, by an independent public accounting firm reasonably acceptable to the Seller and subject to a confidentiality
DEFA14A
2pgor4u 8qestnas82
15 Apr 24
Additional proxy soliciting materials
5:10pm
8-K
xuy9s w1r
22 Feb 24
Departure of Directors or Certain Officers
4:59pm
8-K
EX-2.1
vnyuo2
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am